Sonora Investment Management, LLC - HTG MOLECULAR DIAGNOSTICS IN ownership

HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H104. A total of 44 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q2 2018. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Sonora Investment Management, LLC ownership history of HTG MOLECULAR DIAGNOSTICS IN
ValueSharesWeighting
Q1 2021$3,000
+50.0%
4660.0%0.00%
Q4 2020$2,0000.0%466
-93.3%
0.00%
Q3 2020$2,000
-60.0%
7,0000.0%0.00%
-100.0%
Q2 2020$5,000
+150.0%
7,0000.0%0.00%
Q1 2020$2,000
-60.0%
7,0000.0%0.00%
Q4 2019$5,0000.0%7,0000.0%0.00%
-100.0%
Q3 2019$5,000
-58.3%
7,0000.0%0.00%0.0%
Q2 2019$12,000
-33.3%
7,0000.0%0.00%
-50.0%
Q1 2019$18,0000.0%7,0000.0%0.00%
-33.3%
Q4 2018$18,000
-40.0%
7,000
+16.7%
0.00%
-25.0%
Q3 2018$30,000
+172.7%
6,000
+71.4%
0.00%
+100.0%
Q2 2018$11,000
-99.9%
3,5000.0%0.00%0.0%
Q1 2018$12,670,000
+78.3%
3,5000.0%0.00%
+100.0%
Q4 2017$7,105,000
-24.0%
3,500
-36.4%
0.00%
-50.0%
Q3 2017$9,350,000
+0.4%
5,500
+57.1%
0.00%0.0%
Q2 2017$9,310,000
-61.6%
3,5000.0%0.00%
-60.0%
Q1 2017$24,220,000
+208.9%
3,5000.0%0.01%
+150.0%
Q4 2016$7,840,000
-1.3%
3,5000.0%0.00%0.0%
Q3 2016$7,945,000
-16.5%
3,5000.0%0.00%0.0%
Q2 2016$9,520,000
-6.5%
3,5000.0%0.00%0.0%
Q1 2016$10,185,000
+145400.0%
3,500
+133.3%
0.00%0.0%
Q4 2015$7,000
+133.3%
1,500
+200.0%
0.00%
+100.0%
Q3 2015$3,0005000.00%
Other shareholders
HTG MOLECULAR DIAGNOSTICS IN shareholders Q2 2018
NameSharesValueWeighting ↓
Novo Holdings A/S 1,280,185$9,755,0001.01%
Cormorant Asset Management, LP 201,000$1,532,0000.24%
PUTNAM INVESTMENTS LLC 575,692$4,386,0000.01%
Alyeska Investment Group, L.P. 114,113$870,0000.01%
VANGUARD GROUP INC 4,355,424$131,473,0000.01%
BLACKROCK ADVISORS LLC 463,200$3,530,0000.00%
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) 26,100$199,000,0000.00%
Ironwood Financial, llc 870$7,0000.00%
PANAGORA ASSET MANAGEMENT INC 24,293$185,0000.00%
Sonora Investment Management, LLC 500$3,0000.00%
View complete list of HTG MOLECULAR DIAGNOSTICS IN shareholders